Prenetics Global (NASDAQ:PRE) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Prenetics Global (NASDAQ:PRE) from a buy rating to a hold rating in a research report sent to investors on Monday morning.

Several other brokerages have also commented on PRE. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, January 22nd. Cantor Fitzgerald lifted their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Finally, Roth Mkm initiated coverage on shares of Prenetics Global in a report on Wednesday, February 11th. They issued a “buy” rating and a $36.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $34.00.

Prenetics Global Stock Up 4.8%

PRE opened at $21.97 on Monday. Prenetics Global has a 52 week low of $3.09 and a 52 week high of $22.86. The stock has a market cap of $369.76 million, a PE ratio of -10.82 and a beta of 0.35. The business has a 50 day moving average of $17.41 and a 200-day moving average of $13.74.

Institutional Trading of Prenetics Global

A number of institutional investors and hedge funds have recently bought and sold shares of PRE. Wells Fargo & Company MN purchased a new position in Prenetics Global in the fourth quarter worth about $47,000. JPMorgan Chase & Co. bought a new stake in shares of Prenetics Global during the third quarter valued at approximately $65,000. Stevens Capital Partners purchased a new position in Prenetics Global in the 2nd quarter worth approximately $137,000. T3 Companies LLC bought a new position in Prenetics Global in the 4th quarter valued at approximately $170,000. Finally, Kingsview Wealth Management LLC bought a new position in Prenetics Global in the 4th quarter valued at approximately $172,000. 25.01% of the stock is currently owned by institutional investors.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.